Every Wednesday Asa reviews interesting warning letters and other enforcement trends. He’s been writing this each week for 4+ years, and it is a labor of regulatory love.
We'll never share your email with anyone else. Cancel at any time.
Clinical study parameters can turn a dietary supplement study into a drug study in FDA’s view, triggering Investigational New Drug (IND) requirements. In one FDA Bioresearch Monitoring investigation, a study on a product containing multiple dietary supplement ingredients was treated as a drug because it ...
This is a cautionary tale about a skincare company that relied on a third-party app score and before-and-after images, leading ...
This is a story about a homeopathic manufacturer that was cited for several GMP issues, and about a discarded “sticky ...
A nicotine and caffeine drink company was cited for making disease claims and for selling a “new tobacco product.” I’ve ...
Asa Waldstein is a 24-year veteran of the dietary supplement industry, with experience spanning manufacturing, marketing, and regulatory compliance. He is the principal of Apex Compliance, a software company dedicated to streamlining regulatory marketing compliance for the dietary supplement and natural products sectors. Asa also leads Supplement Advisory Group, a boutique consultancy focused on marketing risk analysis, labeling, and practical compliance strategies for websites and social media. Asa has helped oversee three FDA GMP inspections with no 483s and was honored with the 2023 AHPA Herbal Hero Award and the 2024 What's Up Supps Policy and Change Agent Award. He currently serves as Chair of the American Herbal Products Association’s (AHPA) Technology & AI Innovation Committee.
Upcoming Events
See Asa in person
